JP7874663B2 - PKC-θモジュレーター - Google Patents

PKC-θモジュレーター

Info

Publication number
JP7874663B2
JP7874663B2 JP2023568613A JP2023568613A JP7874663B2 JP 7874663 B2 JP7874663 B2 JP 7874663B2 JP 2023568613 A JP2023568613 A JP 2023568613A JP 2023568613 A JP2023568613 A JP 2023568613A JP 7874663 B2 JP7874663 B2 JP 7874663B2
Authority
JP
Japan
Prior art keywords
hydrogen
alkyl
mmol
haloalkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023568613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518447A5 (cg-RX-API-DMAC7.html
JP2024518447A (ja
Inventor
レイ,ピーター
ブラッドリー,アンソニー
リチャーズ,サイモン
サントス,カタリナ
ベスナード,ジェレミー
メネロル,ジェローム
スショー,ヴィルジニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2024518447A publication Critical patent/JP2024518447A/ja
Publication of JP2024518447A5 publication Critical patent/JP2024518447A5/ja
Application granted granted Critical
Publication of JP7874663B2 publication Critical patent/JP7874663B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Optical Communication System (AREA)
JP2023568613A 2021-05-06 2022-05-06 PKC-θモジュレーター Active JP7874663B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2106486.0 2021-05-06
GB202106486 2021-05-06
PCT/GB2022/051167 WO2022234299A1 (en) 2021-05-06 2022-05-06 Pkc-theta modulators

Publications (3)

Publication Number Publication Date
JP2024518447A JP2024518447A (ja) 2024-05-01
JP2024518447A5 JP2024518447A5 (cg-RX-API-DMAC7.html) 2025-11-18
JP7874663B2 true JP7874663B2 (ja) 2026-06-16

Family

ID=82100804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568613A Active JP7874663B2 (ja) 2021-05-06 2022-05-06 PKC-θモジュレーター

Country Status (14)

Country Link
US (1) US20240239794A1 (cg-RX-API-DMAC7.html)
EP (1) EP4334316A1 (cg-RX-API-DMAC7.html)
JP (1) JP7874663B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240024063A (cg-RX-API-DMAC7.html)
CN (1) CN117295738A (cg-RX-API-DMAC7.html)
AU (1) AU2022269348A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022883A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214088A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003247A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015005A2 (cg-RX-API-DMAC7.html)
IL (1) IL307669A (cg-RX-API-DMAC7.html)
MX (1) MX2023013012A (cg-RX-API-DMAC7.html)
PE (1) PE20250019A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022234299A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240262821A1 (en) * 2021-05-06 2024-08-08 Exscientia Al Limited PKC-Theta Modulators
CN118772140B (zh) * 2023-04-07 2026-04-17 四川大学 一类化合物及其在治疗hDHODH介导的疾病中的用途
WO2025255294A1 (en) * 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Pkc-theta inhibitors, compositions, and methods of use
WO2025255298A1 (en) * 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Pkc-theta inhibitors, compositions, and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502994A (ja) 2007-11-02 2011-01-27 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼC−θとしての[1H−ピラゾロ[3,4−B]ピリジン−4−イル]−フェニレンまたは−ピリジン−2−イル誘導体
JP2013525481A (ja) 2010-05-05 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド PKC−θインヒビターとして有用な4置換ピラゾロピリミジン
WO2020240586A1 (en) 2019-05-28 2020-12-03 Mankind Pharma Ltd. Novel compounds for inhibition of janus kinase 1
WO2022234298A1 (en) 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0920382D0 (en) 2009-11-20 2010-01-06 Univ Dundee Design of molecules
RU2016129380A (ru) 2013-12-20 2018-01-25 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные диаминопиримидильные соединения, их композиции и способы лечения с их участием

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502994A (ja) 2007-11-02 2011-01-27 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼC−θとしての[1H−ピラゾロ[3,4−B]ピリジン−4−イル]−フェニレンまたは−ピリジン−2−イル誘導体
JP2013525481A (ja) 2010-05-05 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド PKC−θインヒビターとして有用な4置換ピラゾロピリミジン
WO2020240586A1 (en) 2019-05-28 2020-12-03 Mankind Pharma Ltd. Novel compounds for inhibition of janus kinase 1
WO2022234298A1 (en) 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators

Also Published As

Publication number Publication date
WO2022234299A1 (en) 2022-11-10
JP2024518447A (ja) 2024-05-01
AU2022269348A1 (en) 2023-10-26
CO2023015005A2 (es) 2024-02-05
US20240239794A1 (en) 2024-07-18
CA3214088A1 (en) 2022-11-10
EP4334316A1 (en) 2024-03-13
MX2023013012A (es) 2024-03-25
IL307669A (en) 2023-12-01
PE20250019A1 (es) 2025-01-07
KR20240024063A (ko) 2024-02-23
BR112023022883A2 (pt) 2024-01-23
CN117295738A (zh) 2023-12-26
CL2023003247A1 (es) 2024-04-26

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260604

R150 Certificate of patent or registration of utility model

Ref document number: 7874663

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150